SARTORIUS’ WELL-OILED M&A MACHINERY QUESTIONED (ADD; 14% UPSIDE)
25/09/23 -" The last time we teased on Sartorius, we believed this high quality bioprocessing asset was still rather expensive even after the 25% drop from its lofty 2021 peaks. In essence, there was little ..."
Pages
65
Language
English
Published on
25/09/23
You may also be interested by these reports :
09/05/25
Sonova’s full-year results slightly exceeded market expectations, with robust growth across both segments. The promising FY2025-26 outlook was well ...
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...